Exelixis Inc (EXEL)

Price$50.28

Value ScoreC

Growth ScoreB

Momentum ScoreB

Favorite Metrics

Price vs S&P 500 (26W)4.89%

Price vs S&P 500 (4W)10.60%

VGM Score61.63

Market Capitalization$12.69B

P/E Ratio (Annual)16.21x

All Metrics

P/CF (Annual)14.35x

Book Value / Share (Quarterly)$7.63

P/TBV (Annual)17.27x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)12.93%

Cash Flow / Share (Quarterly)$3.62

Price vs S&P 500 (YTD)4.24%

Gross Margin (TTM)96.44%

Net Profit Margin (TTM)35.08%

EPS (TTM)$3.02

10-Day Avg Trading Volume2.40M

EPS Excl Extra (TTM)$3.02

Revenue Growth (5Y)10.09%

EPS (Annual)$2.78

ROI (Annual)36.21%

Gross Margin (Annual)96.39%

Net Profit Margin (5Y Avg)18.35%

Cash / Share (Quarterly)$3.06

P/E Basic Excl Extra (TTM)15.22x

Revenue Growth QoQ (YoY)9.97%

EPS Growth (5Y)31.10%

P/E Normalized (Annual)16.21x

ROA (Last FY)27.51%

Revenue Growth TTM (YoY)7.91%

EBITD / Share (TTM)$3.49

ROE (5Y Avg)16.66%

Operating Margin (TTM)39.43%

Cash Flow / Share (Annual)$3.34

P/B Ratio6.55x

P/B Ratio (Quarterly)5.63x

Net Income / Employee (Annual)$726,600

EV / Revenue (TTM)5.25x

Net Interest Coverage (TTM)42.74x

ROA (TTM)30.47%

EPS Growth QoQ (YoY)42.14%

EV / EBITDA (TTM)12.91x

EPS Incl Extra (Annual)$2.78

Current Ratio (Annual)3.56x

Quick Ratio (Quarterly)2.98x

3-Month Avg Trading Volume2.76M

52-Week Price Return18.50%

EV / Free Cash Flow (Annual)14.23x

P/E Incl Extra (TTM)15.22x

Revenue / Employee (TTM)$2,205,700

Tangible BV / Share (Quarterly)$0.69

P/S Ratio (Annual)5.47x

Asset Turnover (Annual)0.82x

52-Week High$52.96

Operating Margin (5Y Avg)19.97%

EPS Excl Extra (Annual)$2.78

CapEx CAGR (5Y)-33.37%

Tangible BV CAGR (5Y)-26.34%

26-Week Price Return20.82%

Quick Ratio (Annual)3.32x

13-Week Price Return14.00%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)3.26x

Enterprise Value$12.46B

Revenue / Share Growth (5Y)13.08%

Asset Turnover (TTM)0.87x

Book Value / Share Growth (5Y)3.50%

Revenue / Employee (Annual)$2,154,200

Inventory Turnover (Annual)2.87x

Pretax Margin (Annual)40.57%

Cash / Share (Annual)$4.03

3-Month Return Std Dev38.56%

Gross Margin (5Y Avg)96.35%

Net Income / Employee (TTM)$773,800

EBITDA CAGR (5Y)24.58%

EBITDA Interim CAGR (5Y)55.08%

ROE (Last FY)36.21%

Net Interest Coverage (Annual)5.08x

EPS Basic Excl Extra (Annual)$2.78

P/FCF (TTM)13.83x

Receivables Turnover (TTM)7.78x

EV / Free Cash Flow (TTM)13.58x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$3.02

Receivables Turnover (Annual)8.09x

ROI (TTM)40.21%

P/S Ratio (TTM)5.34x

Pretax Margin (5Y Avg)23.03%

Revenue / Share (Annual)$8.23

Tangible BV / Share (Annual)$0.52

Forward P/E14.89x

Free OCF CAGR (5Y)21.08%

Price vs S&P 500 (52W)-9.71%

P/E Ratio (TTM)15.22x

EPS Growth TTM (YoY)64.00%

Year-to-Date Return15.17%

5-Day Price Return0.66%

EPS Normalized (Annual)$2.78

ROA (5Y Avg)12.82%

Net Profit Margin (Annual)33.73%

Month-to-Date Return13.54%

Cash Flow / Share (TTM)$0.36

EBITD / Share (Annual)$3.20

EPS Growth (3Y)70.35%

Operating Margin (Annual)37.59%

LT Debt / Equity (Annual)5.07x

P/CF (TTM)13.72x

ROI (5Y Avg)16.66%

P/E Excl Extra (TTM)15.22x

LT Debt / Equity (Quarterly)2.55x

EPS Basic Excl Extra (TTM)$3.02

P/TBV (Quarterly)12.86x

P/B Ratio (Annual)5.44x

Inventory Turnover (TTM)3.28x

Pretax Margin (TTM)42.23%

Book Value / Share (Annual)$8.23

Price vs S&P 500 (13W)4.26%

Net Margin Growth (5Y)15.94%

Beta0.43x

P/FCF (Annual)14.49x

Revenue / Share (TTM)$8.89

ROE (TTM)40.21%

52-Week Low$33.76

vGradeC

gGradeB

mGradeB

vgmGradeB

Show chart for

Earnings Surprise History

Q1 260.79est. 0.72

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

3.74

3.77

Industry Peers — Biological Products(178)

Symbol	Value Score	Growth Score	Momentum Score	Price
EXELExelixis Inc	C	B	B	$50.28
AMGNAmgen Inc	C	C	C	$329.13
GILDGilead Sciences Inc	C	B	C	$131.10
ARGXargenx SE American Depositary Shares	D	A	C	$836.09
RVMDRevolution Medicines, Inc. Common Stock	F	—	A	$163.68
BIIBBiogen Inc. Common Stock	B	D	B	$192.23
BNTXBioNTech SE American Depositary Share	C	C	C	$91.70
MRNAModerna, Inc. Common Stock	C	B	B	$46.06
NBIXNeurocrine Biosciences Inc	C	B	B	$161.00
KRYSKrystal Biotech, Inc. Common Stock	D	B	B	$298.10
TECHBio-Techne Corp.	D	C	C	$50.79

About

Exelixis Inc is a biopharmaceutical company that discovers and commercializes oncology treatments. Its portfolio includes Cabometyx for renal cell and hepatocellular carcinoma, Cometriq for metastatic medullary thyroid cancer, and Cotellic (in partnership with Roche) for melanoma.